Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386711 | 0.90 | CHRNB2 (0.51) | CHRNB2CHRNA4LTA4H | |
| SCHEMBL20550900 | 0.84 | MCHR1 (0.53) | LTA4H | |
| SCHEMBL31434287 | 0.84 | MCHR1 (0.53) | LTA4H | |
| SCHEMBL7373164 | 0.81 | CA12 (0.42) | LTA4H | |
| SCHEMBL8522859 | 0.81 | MAPT (0.44) | LTA4HTSHR | |
| SCHEMBL252784 | 0.81 | GAA (0.39) | — | |
| SCHEMBL31371078 | 0.80 | FDPS (0.40) | FDPS | |
| SCHEMBL17662278 | 0.80 | ALDH1A1 (0.43) | FDPS | |
| SCHEMBL31371000 | 0.79 | PDK2 (0.47) | DRD2 | |
| SCHEMBL3298622 | 0.78 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490557-B1 | COMBINATION THERAPIES FOR TREATING CANCER | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11241421-B2 | Combination therapies for treating cancer | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241421-B2 | Combination therapies for treating cancer | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190343820-A1 | COMBINATION THERAPIES FOR TREATING CANCER | UNIVERSITY OF VIRGINIA | 2019-11-14 | — | — | US | disclosed |
| US-20190343820-A1 | COMBINATION THERAPIES FOR TREATING CANCER | UNIVERSITY OF VIRGINIA | 2019-11-14 | — | — | US | disclosed |
| EP-3490557-A1 | COMBINATION THERAPIES FOR TREATING CANCER | University Of Virginia Patent Foundation (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018022855-A1 | COMBINATION THERAPIES FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022855-A1 | COMBINATION THERAPIES FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343820-A1 | COMBINATION THERAPIES FOR TREATING CANCER | MCL1, MLLT1, FLI1 | CHRNB2 4212/4885CHRNA4 4091/4885KCNH2 2850/4885 |
| US-11241421-B2 | Combination therapies for treating cancer | MCL1, MLLT1, FLI1 | CHRNB2 4212/4885CHRNA4 4091/4885KCNH2 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.